Clin2
NCT06931002Likely a fitRecruiting

Cold virus study in bronchiectasis and healthy volunteers

Bronchiectasis AdultBronchiectasis With Acute ExacerbationBronchiectasis With Chronic Infection With Pseudomonas AeruginosaViral InfectionRhinovirus Infection

Part of Infections, Lungs & breathing clinical trials.

This study tests whether giving a common cold virus (rhinovirus) to people with bronchiectasis and healthy volunteers can trigger a lung flare-up. It aims to understand how the immune system responds and what causes exacerbations, which could lead to better treatments.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
54 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old and have a confirmed diagnosis of bronchiectasis with a severity score of 0–8, OR you are a healthy volunteer.
  • If you have bronchiectasis and carry Pseudomonas in your lungs, you must have had it confirmed on two tests at least 3 months apart within the last 2 years.
  • You are not a current smoker and have not smoked in the past year. If you were a former smoker, your total smoking history is less than 5 pack-years (roughly one pack a day for 5 years).
  • You do not have antibodies to the specific cold virus (RV-A16) used in the study — this will be tested.
  • You are not in close contact with infants or elderly people at home or work.
  • You are not pregnant or breastfeeding.
  • Your bronchiectasis is not due to cystic fibrosis, a primary immune problem, primary ciliary dyskinesia, or allergic bronchopulmonary aspergillosis.
  • You do not have another major lung disease (like interstitial lung disease) that could affect the study.
  • Your lung function (FEV1) is 50% or more of the predicted value.
  • You have not taken antibiotics for a flare-up in the last 6 weeks, or preventive antibiotics in the last 4 weeks.
  • You have not used any corticosteroids (inhaled, nasal, or by mouth) in the last 4 weeks.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07112235Recruiting
COPD and cold virus study

This study looks at how the common cold virus affects people with COPD to find new treatments. If you have moderate COPD and your symptoms flare up when you catch a cold, you may be able to help.

London
NCT06625944Recruiting
How viral infections affect lung disease

This study looks at how viral infections impact people with chronic lung conditions like COPD or bronchiectasis. It aims to understand symptoms and triggers better, which could help improve future treatments.

London
NCT06488118Recruiting
Lung response to inhaled immune stimulant in healthy and asthma

This study tests how the lungs react to breathing in a weak immune-stimulating drug (R848). It includes healthy volunteers and people with mild to moderate asthma to see differences in airway responses.

Cambridge, Cambridgeshire
NCT07610395Recruiting· Phase 2
Testing an oral drug for cold virus in COPD patients

This trial tests an oral medication (VPV) to see if it can safely treat rhinovirus (a common cold virus) in people with COPD. The goal is to help you recover faster and prevent serious COPD flare-ups.

Mobile, Alabama
NCT07059767Recruiting· Phase 2
Nasal spray for asthma symptoms from colds

This trial tests if an investigational nasal spray (ETH47) can reduce asthma symptoms triggered by a common cold virus (rhinovirus). You will be exposed to the virus in a safe setting to see if the spray helps control your asthma.

London
NCT07488897Recruiting· Phase 1/Phase 2
Testing RIG-101 in healthy adults and adults with asthma

This trial tests an experimental medicine called RIG-101 in healthy adults and adults with asthma. The goal is to see if it can safely prevent or reduce asthma worsening after exposure to a common cold virus (rhinovirus).

London

Hear when a new Bronchiectasis Adult trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.